Investor Presentation
Perth, July 21, 2016 AEST (ABN Newswire) - MMJ PhytoTech Ltd (
ASX:MMJ) are pleased to provide the Company's latest Investor Presentation for July 2016, 'From Farm to Pharma'.
MMJ PhytoTech at a Glance
- MMJ PhytoTech('MMJ') is a vertically-integrated biopharmaceutical company focused on developing and commercializing Medical Cannabis ('MC') based therapeutics
- The Company was formed from the July 2015 merger of MMJ Bioscience (Can PrivCo) and PhytoTech Medical (Aust. PubCo) and is traded on the ASX under the symbol 'MMJ'
- MMJ's unique "Farm to Pharma" strategic platform integrates the entire MC pharmaceutical supply chain combining MC cultivation with pharmaceutical processing / advanced delivery technologies and R&D / clinical development -unlocking the full value of the Company's MMPR assets
- The "Farm to Pharma" integration is essential for the development and supply of MC-based pharmaceuticals but also provides the company with several near-and mid-term pre-pharma revenue sources
- Currently, MMJ is ramping up production at its MMPR facility in Canada, growing revenues from sales of its exclusive Gelpell(R) CBD Capsules in the EU and preparing for the Q4 2016/Q1 2017 commencement of two Phase 2 Clinical trials using Gelpell(R) THC/CBD and Gelpell(R) CBD capsule for MS and Epilepsy indications respectively
To view the presentation, please visit:
http://abnnewswire.net/lnk/X40506B6
About MMJ Group Holdings Ltd
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/
| ||
|
